Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Increased risk of osteoporosis following commonly used first-line treatments for lymphoma : a Danish Nationwide Cohort Study. / Baech, Joachim; Hansen, Steen Moeller; Jakobsen, Lasse Hjort; Øvlisen, Andreas K; Severinsen, Marianne Tang; Brown, Peter de Nully; Vestergaard, Peter; Frederiksen, Henrik; Jørgensen, Judit; Starklint, Jørn; Josefsson, Pär; Hammer, Troels; Clausen, Michael Roost; Torp-Pedersen, Christian; Jensen, Paw; El-Galaly, Tarec Christoffer.
In: Leukemia and Lymphoma, Vol. 61, No. 6, 2020, p. 1345-1354.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Increased risk of osteoporosis following commonly used first-line treatments for lymphoma
T2 - a Danish Nationwide Cohort Study
AU - Baech, Joachim
AU - Hansen, Steen Moeller
AU - Jakobsen, Lasse Hjort
AU - Øvlisen, Andreas K
AU - Severinsen, Marianne Tang
AU - Brown, Peter de Nully
AU - Vestergaard, Peter
AU - Frederiksen, Henrik
AU - Jørgensen, Judit
AU - Starklint, Jørn
AU - Josefsson, Pär
AU - Hammer, Troels
AU - Clausen, Michael Roost
AU - Torp-Pedersen, Christian
AU - Jensen, Paw
AU - El-Galaly, Tarec Christoffer
PY - 2020
Y1 - 2020
N2 - High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.
AB - High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.
U2 - 10.1080/10428194.2020.1723015
DO - 10.1080/10428194.2020.1723015
M3 - Journal article
C2 - 32043382
VL - 61
SP - 1345
EP - 1354
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 6
ER -
ID: 255556082